Cross-dressing of dendritic cells strengthens antitumor immunity

Hongli Yin; Hongcheng Cheng; Yuqian Wang; Guideng Li

doi:10.1016/j.trecan.2022.01.001

Cross-dressing of dendritic cells strengthens antitumor immunity

Trends Cancer. 2022 Mar;8(3):159-160. doi: 10.1016/j.trecan.2022.01.001. Epub 2022 Jan 31.

Authors

Hongli Yin¹, Hongcheng Cheng¹, Yuqian Wang¹, Guideng Li²

Affiliations

¹ CAMS Key Laboratory of Synthetic Biology Regulatory Element, Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China; Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China.
² CAMS Key Laboratory of Synthetic Biology Regulatory Element, Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China; Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China. Electronic address: [email protected].

PMID: 35115254
DOI: 10.1016/j.trecan.2022.01.001

Abstract

Different subsets of tumor-infiltrating dendritic cells (DCs) influence immune response and tolerance in cancer settings. Duong et al. discovered that conventional DC2 subset (cDC2s) can differentiate into stimulatory interferon-stimulated gene (ISG)⁺ DCs by type I interferon (IFN-I) produced in regressor tumors and acquire and present tumor-derived peptide-MHC (pMHC) class I complexes to increase the protective antitumor CD8⁺ T cell response.

Keywords: CD8(+) T cells; ISG(+) DCs; cancer immunotherapy; cross-dressing.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Bandages
CD8-Positive T-Lymphocytes*
Dendritic Cells*
Humans
Immune Tolerance